Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Nov;21(11):1981-3.
doi: 10.1038/mt.2013.227.

Enhanced oncolytic virotherapy through oxidative stress inhibition

Kendra L Congdon  1 , John H Sampson
Affiliations
Comment

Enhanced oncolytic virotherapy through oxidative stress inhibition

Kendra L Congdon et al. Mol Ther. 2013 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The antioxidant N-acetylcysteine amide (NACA) reduces oxidative stress within CRAd-S-pk7 infected neural stem cells to enhance oncolytic virotherapy of glioma. Glioma-tropic neural stem cells (NSCs) are infected with oncolytic virus (CRAd-S-pk7) and used as carriers for viral delivery to the tumor. Cell carriers in oncolytic virotherapy (OV) can protect virus from host immune-mediated clearance and permit viral replication to boost titers, resulting in improved viral delivery and intratumoral spread. However, infection triggers reactive oxygen species (ROS) in NSCs, with consequent expression of proapoptotic proteins and signaling pathways associated with oxidative stress. NACA reduces ROS within NSCs, with consequent increases in NSC viability, viral release, intratumoral viral spread, and enhanced median survival in a preclinical model of orthotopic glioma. Thus, oxidative stress has been identified as a novel therapeutic target in cell carrier–mediated OV.
See this image and copyright information in PMC

Comment on

References

    1. Kim CK, Ahmed AU, Auffinger B, Ulasov IV, Tobias AL, Moon K-S.et al. (2013N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy Mol Ther 212063–2073. - PMC - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ.et al. (2005Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352987–996. - PubMed
    1. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA.et al. (2007Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 254722–4729. - PubMed
    1. Russell SJ, Peng KW., and, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658–670. - PMC - PubMed
    1. Alvarez-Breckenridge C, Kaur B., and, Chiocca EA. Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev. 2009;109:3125–3140. - PMC - PubMed

MeSH terms

LinkOut - more resources